Cargando…
A glyco-engineered anti-HER2 monoclonal antibody (TrasGEX) induces a long-lasting remission in a patient with HER2 overexpressing metastatic colorectal cancer after failure of all available treatment options
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BMJ Publishing Group
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4717383/ https://www.ncbi.nlm.nih.gov/pubmed/26386048 http://dx.doi.org/10.1136/jclinpath-2015-202996 |
| _version_ | 1782410645610692608 |
|---|---|
| author | Eisner, Florian Pichler, Martin Goletz, Steffen Stoeger, Herbert Samonigg, Hellmut |
| author_facet | Eisner, Florian Pichler, Martin Goletz, Steffen Stoeger, Herbert Samonigg, Hellmut |
| author_sort | Eisner, Florian |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4717383 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2015 |
| publisher | BMJ Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-47173832016-01-28 A glyco-engineered anti-HER2 monoclonal antibody (TrasGEX) induces a long-lasting remission in a patient with HER2 overexpressing metastatic colorectal cancer after failure of all available treatment options Eisner, Florian Pichler, Martin Goletz, Steffen Stoeger, Herbert Samonigg, Hellmut J Clin Pathol PostScript BMJ Publishing Group 2015-12 2015-09-18 /pmc/articles/PMC4717383/ /pubmed/26386048 http://dx.doi.org/10.1136/jclinpath-2015-202996 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| spellingShingle | PostScript Eisner, Florian Pichler, Martin Goletz, Steffen Stoeger, Herbert Samonigg, Hellmut A glyco-engineered anti-HER2 monoclonal antibody (TrasGEX) induces a long-lasting remission in a patient with HER2 overexpressing metastatic colorectal cancer after failure of all available treatment options |
| title | A glyco-engineered anti-HER2 monoclonal antibody (TrasGEX) induces a long-lasting remission in a patient with HER2 overexpressing metastatic colorectal cancer after failure of all available treatment options |
| title_full | A glyco-engineered anti-HER2 monoclonal antibody (TrasGEX) induces a long-lasting remission in a patient with HER2 overexpressing metastatic colorectal cancer after failure of all available treatment options |
| title_fullStr | A glyco-engineered anti-HER2 monoclonal antibody (TrasGEX) induces a long-lasting remission in a patient with HER2 overexpressing metastatic colorectal cancer after failure of all available treatment options |
| title_full_unstemmed | A glyco-engineered anti-HER2 monoclonal antibody (TrasGEX) induces a long-lasting remission in a patient with HER2 overexpressing metastatic colorectal cancer after failure of all available treatment options |
| title_short | A glyco-engineered anti-HER2 monoclonal antibody (TrasGEX) induces a long-lasting remission in a patient with HER2 overexpressing metastatic colorectal cancer after failure of all available treatment options |
| title_sort | glyco-engineered anti-her2 monoclonal antibody (trasgex) induces a long-lasting remission in a patient with her2 overexpressing metastatic colorectal cancer after failure of all available treatment options |
| topic | PostScript |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4717383/ https://www.ncbi.nlm.nih.gov/pubmed/26386048 http://dx.doi.org/10.1136/jclinpath-2015-202996 |
| work_keys_str_mv | AT eisnerflorian aglycoengineeredantiher2monoclonalantibodytrasgexinducesalonglastingremissioninapatientwithher2overexpressingmetastaticcolorectalcancerafterfailureofallavailabletreatmentoptions AT pichlermartin aglycoengineeredantiher2monoclonalantibodytrasgexinducesalonglastingremissioninapatientwithher2overexpressingmetastaticcolorectalcancerafterfailureofallavailabletreatmentoptions AT goletzsteffen aglycoengineeredantiher2monoclonalantibodytrasgexinducesalonglastingremissioninapatientwithher2overexpressingmetastaticcolorectalcancerafterfailureofallavailabletreatmentoptions AT stoegerherbert aglycoengineeredantiher2monoclonalantibodytrasgexinducesalonglastingremissioninapatientwithher2overexpressingmetastaticcolorectalcancerafterfailureofallavailabletreatmentoptions AT samonigghellmut aglycoengineeredantiher2monoclonalantibodytrasgexinducesalonglastingremissioninapatientwithher2overexpressingmetastaticcolorectalcancerafterfailureofallavailabletreatmentoptions AT eisnerflorian glycoengineeredantiher2monoclonalantibodytrasgexinducesalonglastingremissioninapatientwithher2overexpressingmetastaticcolorectalcancerafterfailureofallavailabletreatmentoptions AT pichlermartin glycoengineeredantiher2monoclonalantibodytrasgexinducesalonglastingremissioninapatientwithher2overexpressingmetastaticcolorectalcancerafterfailureofallavailabletreatmentoptions AT goletzsteffen glycoengineeredantiher2monoclonalantibodytrasgexinducesalonglastingremissioninapatientwithher2overexpressingmetastaticcolorectalcancerafterfailureofallavailabletreatmentoptions AT stoegerherbert glycoengineeredantiher2monoclonalantibodytrasgexinducesalonglastingremissioninapatientwithher2overexpressingmetastaticcolorectalcancerafterfailureofallavailabletreatmentoptions AT samonigghellmut glycoengineeredantiher2monoclonalantibodytrasgexinducesalonglastingremissioninapatientwithher2overexpressingmetastaticcolorectalcancerafterfailureofallavailabletreatmentoptions |